Salvatore Siena
Università degli Studi di Milano
H-index: 109
Europe-Italy
Top articles of Salvatore Siena
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real … | JCO Precision Oncology | Allan Hackshaw Otto Fajardo Urania Dafni Hans Gelderblom Pilar Garrido | 2024/1 |
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer | Clinical Lung Cancer | Yun Fan Alexander Drilon Chao-Hua Chiu Herbert HF Loong Salvatore Siena | 2024/3/1 |
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial | Journal of Clinical Oncology | Funda Meric-Bernstam Vicky Makker Ana Oaknin Do-Youn Oh Susana Banerjee | 2024/1/1 |
Ongoing clinical trials and future research scenarios of circulating tumor DNA for the treatment of metastatic colorectal cancer | Laura Roazzi Giorgio Patelli Katia Bruna Bencardino Alessio Amatu Erica Bonazzina | 2024/2/16 | |
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with … | BMC cancer | Monica Niger Federico Nichetti Lorenzo Fornaro Chiara Pircher Federica Morano | 2024/4/8 |
Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers | Journal of Clinical Pathology | Gianluca Mauri Giorgio Patelli Laura Roazzi Emanuele Valtorta Alessio Amatu | 2024/2/13 |
OC. 04.2: EFFECT OF PREOPERATIVE CHEMO-RADIATION ON TUMORINFILTRATING LYMPHOCYTES IN LOCALLY ADVANCED RECTAL CANCER AND TUMOR RESPONSE: RESULTS FROM THE STAR-01 COHORT | Digestive and Liver Disease | F Negri L Gnetti N Campanini C Azzoni L Bottarelli | 2024/4/1 |
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells | Cell Reports Medicine | Alberto Sogari Emanuele Rovera Gaia Grasso Elisa Mariella Nicole Megan Reilly | 2024/1/15 |
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial | JAMA Network Open | Davide Ciardiello Erika Martinelli Teresa Troiani Gianluca Mauri Daniele Rossini | 2024/4/1 |
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review | Davide Ciardiello Gianluca Mauri Andrea Sartore-Bianchi Salvatore Siena Maria Giulia Zampino | 2024/1/12 | |
Development and validation of an artificial-intelligence-based pathomics biomarker to predict resistance to first-line treatment in metastatic colorectal cancer | Cancer Communications | Quirino Lai Carmine De Stefano Jean Emond Prashant Bhangui Toru Ikegami | 2023/12 |
654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the … | Annals of Oncology | BT Li F Meric-Bernstam A Bardia Y Naito S Siena | 2023/10/1 |
Targeting HER2 heterogeneity in breast and gastrointestinal cancers | Carmine Valenza Lorenzo Guidi Elena Battaiotto Dario Trapani Andrea Sartore Bianchi | 2023/11/25 | |
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review | Caterina Vaghi Gianluca Mauri Alberto Giuseppe Agostara Giorgio Patelli Elio Gregory Pizzutilo | 2023/1/1 | |
72P Molecular characterization of advanced primary cardiac sarcomas | ESMO Open | AG Agostara G Patelli K Bencardino C Lauricella S Pierri | 2023/3/1 |
High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study. | Andrea Sartore-Bianchi Alessio Amatu Federica Di Nicolantonio Teresa Troiani Federica Tosi | 2023/6/1 | |
Adjuvant nab-paclitaxel+ gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial | Journal of Clinical Oncology | Margaret A Tempero Uwe Pelzer Eileen M O'Reilly Jordan Winter Do-Youn Oh | 2023/4/4 |
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer | J. Clin. Oncol | Tanios S Bekaii-Saab Eric Van Cutsem Josep Tabernero Salvatore Siena Takayuki Yoshino | 2023/6/1 |
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. | Funda Meric-Bernstam Vicky Makker Ana Oaknin Do-Youn Oh Susana N Banerjee | 2023/6/10 | |
223P Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers | Annals of Oncology | G Mauri V Giannini G Nicoletti L Lazzari A Sartore Bianchi | 2023/10/1 |
Co-Authors
